November 9, 2026
Business

Piramal Pharma points to early recovery signs after seeing red in Q3(Soban News)

The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹2,140 crore, and slipping to a loss of ₹136 crore from a net profit of ₹4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal.

​The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹2,140 crore, and slipping to a loss of ₹136 crore from a net profit of ₹4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal. by Soban News (international And National News)

Related posts

ELSS funds see ₹650 crore outflow; are tax-saving mutual funds losing relevance?(Soban News)

News-Soban-Admin

MCX shares rise 2% as JPMorgan upgrades, raises target price after this Sebi proposal(Soban News)

News-Soban-Admin

Autism Tied to Psychosis Spectrum at Both Trait and Diagnostic Levels – EMJ(Soban News)

News-Soban-Admin

Leave a Comment